FDA
-
-
-
-
-
-
-
Guerbet: 2022 annual results
-
-
-
-
-
-
-
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
-
-
-
-
-
-
-
Global Blood's (GBT) Oxbryta Granted Marketing Authorization in UK
-
-
-
-
-
-
-
NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell Disease
-
-
-
-
-
-
-
Global Blood Therapeutics (GBT) Granted FDA FDA Orphan Drug and Rare Pediatric Disease Designations for Inclacumab and GBT601
-
-
-
-
-
-
-
GBT Reports First Quarter 2022 Financial Results
-
-
-
-
-
-
-
GBT Announces New Employment Inducement Grants
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

